Portola Pharmaceuticals, Inc. (PTLA) Position Trimmed by Candriam Luxembourg S.C.A.

Candriam Luxembourg S.C.A. reduced its position in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) by 1.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 128,500 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the quarter. Candriam Luxembourg S.C.A. owned 0.22% of Portola Pharmaceuticals worth $6,943,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Hanseatic Management Services Inc. raised its position in Portola Pharmaceuticals by 0.3% in the 2nd quarter. Hanseatic Management Services Inc. now owns 22,800 shares of the biopharmaceutical company’s stock worth $1,281,000 after purchasing an additional 70 shares during the period. IFP Advisors Inc raised its position in Portola Pharmaceuticals by 7.7% in the 2nd quarter. IFP Advisors Inc now owns 2,370 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 170 shares during the period. Principal Financial Group Inc. raised its position in Portola Pharmaceuticals by 0.3% in the 1st quarter. Principal Financial Group Inc. now owns 62,322 shares of the biopharmaceutical company’s stock worth $2,442,000 after purchasing an additional 202 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Portola Pharmaceuticals by 14.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,078 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 258 shares during the period. Finally, Legal & General Group Plc increased its position in shares of Portola Pharmaceuticals by 1.6% during the first quarter. Legal & General Group Plc now owns 18,364 shares of the biopharmaceutical company’s stock worth $719,000 after acquiring an additional 290 shares during the period. 86.04% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Portola Pharmaceuticals, Inc. (PTLA) Position Trimmed by Candriam Luxembourg S.C.A.” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.themarketsdaily.com/2017/11/13/portola-pharmaceuticals-inc-ptla-position-trimmed-by-candriam-luxembourg-s-c-a.html.

Shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) traded up $1.39 during mid-day trading on Monday, reaching $48.95. 518,000 shares of the company traded hands, compared to its average volume of 995,279. The company has a debt-to-equity ratio of 0.24, a quick ratio of 8.31 and a current ratio of 8.31. Portola Pharmaceuticals, Inc. has a 12 month low of $17.15 and a 12 month high of $67.10.

Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.49) by $0.08. The company had revenue of $3.83 million for the quarter, compared to analyst estimates of $4.71 million. Portola Pharmaceuticals had a negative net margin of 938.19% and a negative return on equity of 110.46%. Portola Pharmaceuticals’s revenue was down 58.9% compared to the same quarter last year. During the same period last year, the company posted ($1.64) earnings per share. sell-side analysts anticipate that Portola Pharmaceuticals, Inc. will post -4.95 earnings per share for the current fiscal year.

A number of equities analysts have recently commented on the stock. BidaskClub raised shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, July 24th. Morgan Stanley reaffirmed an “overweight” rating and set a $81.00 target price (up from $75.00) on shares of Portola Pharmaceuticals in a research report on Friday, October 6th. Credit Suisse Group raised shares of Portola Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $70.00 target price on the stock in a research report on Wednesday, August 23rd. Oppenheimer Holdings, Inc. raised their target price on shares of Portola Pharmaceuticals from $66.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, July 24th. Finally, Zacks Investment Research lowered shares of Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Portola Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $65.15.

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply